The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

BMC Endocrine Disorders

Table 2 Meta-regression analysis

	estimate	se	zval	pval	ci.lb	ci.ub
Region of publication (Europe vs. America vs. Asia)	−0.5757	2.4462	−0.2354	0.8139	−5.3702	4.2187
Year of publication (Before 2000 vs. after 2000)	−2.8189	1.4811	−1.9032	0.057	−5.7218	0.084
Tumor size (< 24 vs. ≥24 months)	−0.6388	1.0198	−0.6263	0.5311	−2.6376	1.3601
Drug type (bromocriptine vs. cabergoline)	−1.9056	1.5734	−1.2111	0.2258	−4.9895	1.1783
Treatment duration (< 24 vs. ≥24 months)	−1.0916	1.0284	−1.0614	0.2885	−3.1072	0.9241
Follow-up time (< 12 vs. 12–24 vs. < 24 months)	0.814	1.2451	0.6538	0.5132	−1.6263	3.2544

se: standard error; zval: z value; pval: p value; ci.lb.: Lower bounds of 95% confidential interval; ci.ub: Upper bounds of 95% confidential interval;

ISSN: 1472-6823